EXEL

Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.

Retrieved on: 
Sunday, July 23, 2023
Other Health, General Health, Professional Services, Pharmaceutical, Oncology, Other Professional Services, Science, Legal, Biotechnology, FDA, Other Science, Health, Agreement, Justice, U.S. Department of Agriculture Cotton Annex, U.S. Department of Justice Office of Legislative Affairs, Tablet, District court, Patent, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., ANDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Douglas v. U.S. District Court ex rel Talk America, Food, EXEL, Generic drug, Teva, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva).
  • This settlement resolves patent litigation brought by Exelixis in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents.
  • Additionally, in accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Exelixis and Teva regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware.
  • The Agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

Retrieved on: 
Tuesday, July 18, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, Internet, Calendar, PIN, News, EXEL, Software, Video game, Broadcasting, Cryptocurrency, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close.
  • ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • To access the live webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
  • A webcast replay of the conference call will also be archived on www.exelixis.com for one year.

EXEL Industries: Acquisition of French family group Devaux

Retrieved on: 
Thursday, June 8, 2023
Hozelock, Flower, Snow, Supermarket, Sale, Wood, Gardening, Acquisition, Soil, Leisure, Growth, Environment, Family, EXEL, Management, Duchesnay, Devaux

EXEL Industries today announces the acquisition of an 81% majority stake in Devaux, a French family-owned group specializing in the manufacture and sale of gardening tools.

Key Points: 
  • EXEL Industries today announces the acquisition of an 81% majority stake in Devaux, a French family-owned group specializing in the manufacture and sale of gardening tools.
  • The Devaux Group was formed in 1992 following the takeover of Duchesnay, a manufacturer of graden tools founded in 1923, by Établissements Devaux, a company trading in garden tools founded in 1964.
  • We are proud to join a family-owned group with which we share core values: operational excellence, service culture, respect for the environment and a passion for French industrial know-how.”
    The Devaux group will become a subsidiary of Hozelock EXEL and will operate alongside the other brands of the EXEL Industries Group Garden business: Hozelock, G.F., Berthoud and Tricoflex.
  • Jean-Luc Devaux, currently Devaux group Chairman of the Board, will be Chief Executive Officer of the new entity.

Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board

Retrieved on: 
Wednesday, May 31, 2023
Banking, Professional Services, Finance, Farallon Capital, Annual Meetings of the International Monetary Fund and the World Bank Group, Farallon, Annual general meeting, L.L.C, Exelixis, Patient, Glenview Capital Management, EXEL, Holding company

Farallon Capital Management, L.L.C.

Key Points: 
  • Farallon Capital Management, L.L.C.
  • (“Farallon”) manages funds that own approximately 7.8% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the “Company”), making it the Company’s largest active shareholder.
  • Farallon today commented on the preliminary results of Exelixis’ 2023 Annual Meeting of Shareholders (the “Annual Meeting”), including the election to the Board of Directors (the “Board”) of all three Farallon director candidates: Tom Heyman, Dave Johnson and Bob Oliver.
  • “We are pleased that our three exceptional nominees were elected to the Board of Exelixis and would like to thank our fellow shareholders for their engagement and overwhelming support at the Annual Meeting.

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June

Retrieved on: 
Tuesday, May 30, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Calendar, Goldman Sachs, ET, Exelixis, Conference, News, EXEL, Software, Cryptocurrency

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June:

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June:
    William Blair 43rd Annual Growth Stock Conference: Exelixis is scheduled to present at 10:20 am ET / 9:20 am CT/ 7:20 am PT on Tuesday, June 6 in Chicago.
  • 2023 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 10:30 am ET/ 7:30 am PT on Wednesday, June 7 in New York.
  • Goldman Sachs 44th Annual Global Healthcare Conference: Exelixis is scheduled to present at 7:00 pm ET / 4:00 pm PT on Tuesday, June 13 in Dana Point, CA.
  • To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

Farallon Capital Management Comments on Successful Campaign for Change at Exelixis

Retrieved on: 
Monday, May 8, 2023
Banking, Professional Services, Finance, Share repurchase, Farallon Capital, L.L.C, Farallon, Annual general meeting, Patient, EXEL, Management, Exelixis

(“Farallon”) own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the “Company”), making it the Company’s largest active shareholder.

Key Points: 
  • (“Farallon”) own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the “Company”), making it the Company’s largest active shareholder.
  • Farallon nominated three exceptional candidates for election to the Exelixis Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders, which will be held on May 31, 2023.
  • “This election is about catalyzing change at a company that has long resisted making meaningful adjustments to its R&D priorities and capital allocation approach.
  • We believe he will be an exceptional addition, and together with Farallon candidates Tom Heyman and Bob Oliver, will help drive long-overdue change at Exelixis.

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Retrieved on: 
Sunday, May 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Annual Meetings of the International Monetary Fund and the World Bank Group, Farallon, Annual general meeting, Exelixis, Farallon Capital, EXEL, Management

has informed the Board of Directors of his decision to resign from the Board, effective immediately.

Key Points: 
  • has informed the Board of Directors of his decision to resign from the Board, effective immediately.
  • As previously announced, the Board nominated two of Farallon’s originally proposed candidates – Tomas Heyman and Robert Oliver – to replace two of its existing directors at the Annual Meeting.
  • Following the upcoming Annual Meeting, five directors will have transitioned off the Board in the past three years, and four new independent directors will have been elected, including all of Farallon’s nominees.
  • The Board supports Dr. Willsey’s decision, which will end the need for Farallon to continue its proxy campaign.

Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023

Retrieved on: 
Wednesday, May 3, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Calendar, Bank of America, BofA Securities, Exelixis, Conference, News, EXEL, Software, Pharmaceutical industry, Online shopping, Cryptocurrency

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m.
  • ET / 10:40 a.m. PT.
  • To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
  • A replay will also be available at the same location for at least 30 days.

Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Finance, Health, Professional Services, Oncology, Business development, Optimism, Society, Ōtsuka, Telephone, Perception, Confidentiality, Judgement, Capital allocation line, ASCO, Internet, Farallon, OF, American Society of Clinical Oncology, Patient, Janssen Pharmaceuticals, Our Boarding House, Conference, EXEL, Risk management, Fine chemical, Pharmaceutical industry, Management, Cryptocurrency, Exelixis

Lack of a Clearly Articulated R&D and Capital Allocation Strategy: Exelixis has failed to communicate a coherent R&D strategy to the investment community.

Key Points: 
  • Lack of a Clearly Articulated R&D and Capital Allocation Strategy: Exelixis has failed to communicate a coherent R&D strategy to the investment community.
  • We appreciate that Exelixis responded to our call to return capital (even if belatedly), but it should distribute even more to ensure more focus.
  • At every turn, Exelixis has sought to minimize change and preserve its discretion to resist outside influence.
  • We urge shareholders to vote “FOR” each of the Farallon Nominees on the WHITE Proxy Card and to “WITHHOLD” on Lance Willsey.

Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Retrieved on: 
Tuesday, April 25, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, Internet, Calendar, PIN, News, EXEL, Software, Video game, Broadcasting, Cryptocurrency, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close.
  • ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • To access the live webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.
  • A webcast replay of the conference call will also be archived on www.exelixis.com for one year.